zaltenibart

Monoclonal antibody

Weakdesign only

Evidence outlook · no controlled comparison

NCT05972967 · Paroxysmal Nocturnal Hemoglobinuria

The lead study produced no formal comparison against a control: it had a single arm, or its primary endpoint did not compare the groups (for example, a safety count). This tier describes the design, not an outcome.

NCT05972967: This was a single-arm, open-label study with no comparison group in about 12 patients, and its primary measure was safety and tolerability, so it makes no controlled test of whether zaltenibart works. The interim report describes the drug as well tolerated, with treatment-related side effects in 46.2% of patients, mostly mild to moderate.

Interim results from a conference abstract (ASH 2024, data cut-off 8 July 2024); the registry posts no results and final data are not public.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Paroxysmal Nocturnal Hemoglobinuria
Phase 1 (1)
Paroxysmal Nocturnal Hemoglobinuria

Competitive landscape

This drug's own stage for Paroxysmal Nocturnal Hemoglobinuria: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zaltenibart: this drugPhase 2Monoclonal antibodyMASP-3Weak signal
NCT05972967: Interim (data cut-off 8 July 2024): primary endpoints were safety and tolerability; zaltenibart was well tolerated, treatment-related adverse events in 46.2% of patients (mostly mild to moderate), 1 discontinuation for a treatment-emergent serious adverse event. Hemoglobin rose from a mean baseline of 9.26 g/dL by 3.39 g/dL at day 29 and 3.27 g/dL at day 169 on add-on to ravulizumab (N=13), and by 3.85 g/dL at day 309 on monotherapy (N=6, P=0.003).
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Weak signalFeatured results are safety only in this race
Iptacopan (Fabhalta)ApprovedSmall moleculeComplement Factor BPartial signal
NCT04558918: At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries.
NCT04820530: Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator.
Pegcetacoplan (Empaveli)ApprovedPeptideComplement C3Partial signal
NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666)
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
HRS-5965Phase 3UndisclosedComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
ALN-CFBPhase 1/2RNA / oligonucleotideComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.